Dr. Jay Bhattacharya, acting C. D. C. director, delayed a study showing 50-55% reduction in Covid hospitalizations after officials criticized its methodology.

The report, originally slated for March 19 in the Morbidity and Mortality Weekly Report, analyzed emergency care data to assess vaccine impact. Critics argue the observational approach risks overstating benefits, while Dr. Bhattacharya insists randomized trials—now stalled due to low enrollment—are the gold standard. Pfizer and BioNTech halted their updated shot trial last week, compounding delays in real-world efficacy data. The hold has sparked internal tension, as the White House seeks to minimize vaccine debates ahead of elections. Dr. Debra Houry, former C.

D. C. chief medical officer, called the delay unusual, noting political appointees rarely intervene in journal reviews. HHS spokesperson Andrew Nixon defended the process, stating concerns about methodology are standard but emphasized the study’s scientific validity. **NIH and C. D.

C. leadership conflicts** highlight ongoing challenges in coordinating public health messaging amid staffing shortages and emerging variants.